Back

Unmasking patients insight into SGLT2 inhibitors- a collaborative quality improvement project to enhance patient education and safety

31 August 2024 (18:00 - 18:50)
Organised by: Logo
Congress Presentation Part of: Heart failure: bench to bedside Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Lior Saad

University Hospital of Coventry and Warwickshire, Coventry (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Dual pathway inhibition in patients with atherosclerosis with and without heart failure: insights from the XATOA Registry
Doctor P. Gouda (Edmonton, CA)
Abstract Slides Video
Presentation thumbnail
A newly developed small-molecule ErbB4 agonist reduces reactive cardiac fibrosis and adverse ventricular remodelling after myocardial infarction in a sex-specific manner.
Miss B. Goovaerts (Antwerp, BE)
Abstract Slides Video
Presentation thumbnail
A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
Professor J. Udelson (Boston, US)
Abstract Slides Video
Presentation thumbnail
Long-acting CRF2 receptor agonist COR-1389 improves cardiopulmonary function parameters in monocrotaline-induced pulmonary hypertension and right heart failure rat model
Doctor M. Kowala (Zionsville, US)
Abstract Slides Video
Presentation thumbnail
Heart failure treatment in the last years of life - a nationwide study of 364,000 individuals
Doctor D. Lindholm (Norrtalje, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: bench to bedside

The Event

Event poster

ESC Congress 2024

31 August 2024 18:00 CET
You may be interested in
thumbnail
Congress Presentation
Assessing doctors' knowledge and confidence regarding SGLT2 inhibitor prescribing practices, side-effects, and ESC guidelines
thumbnail
Congress Presentation
Initiation of SGLT2I during acute HF hospitalization or in the immediate period following discharge.
thumbnail
Congress Presentation
A broader benefit: from heart failure to wider cardio-renal-metabolic (CRM) conditions

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources